| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | TA |
| ID number | 4066 |
Provisional Schedule
| Expected publication | 11 October 2023 |
Project Team
| Project lead | Thomas Feist |
Email enquiries
- If you have any queries please email TAteam1@nice.org.uk
Stakeholders
| Companies sponsors | AstraZeneca |
| Patient carer groups | Ovacome |
| Target Ovarian Cancer | |
| Professional groups | Association of Cancer Physicians |
| British Gynaecological Cancer Society | |
| Cancer Research UK | |
| Royal College of Physicians | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
| National Institute for Health Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 August 2023 | Committee meeting: 2 |
| 27 June 2023 - 12 July 2023 | Draft guidance |
| 06 June 2023 | Committee meeting: 1 |
| 27 September 2022 | Invitation to participate |
| 24 August 2022 | Draft scope documents |
| 06 April 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 06 April 2022 | In progress. Review of TA693 |
For further information on our processes and methods, please see our CHTE processes and methods manual